China's booster shot for drug innovation

Different approach

Sunshine Lake Pharma, a Guangdong-based drugmaker that began as a generic medicine producer, offers a different insight into the industry's maturation.

Zhang Yingjun, chairman of the company, said innovative drug R&D is now largely bankrolled by revenues from its generic drug business, supplemented by pre-IPO shareholder backing, platform-based financing and government grants.

The inclusion of its insulin products in the nation's centralized bulk-buy procurement program has secured large supply contracts with public hospitals, providing a stable profit stream. Last year alone, insulin sales generated 244 million yuan in revenue, up about 78.7 percent year-on-year.

"The strong cash flow feeds back into R&D, creating a virtuous cycle that sustains long-term growth," he said.

That revenue is expected to climb further, buoyed by overseas market penetration. The company has passed multiple on-site Good Manufacturing Practice inspections conducted by US and European Union drug regulators, and its insulin product officially received FDA clearance this year. The company projects sales of $30 million by year-end and more than $500 million by 2030.

Innovation and overseas expansion are now seen as two pillars for future growth, according to company executives. The company has so far secured regulatory approval for four novel drugs from China's National Medical Products Administration, three of which were authorized over the past year.

Given the intensifying competition in the biotech sector, Zhang said it is crucial to differentiate products in the pipeline. The three recently approved drugs all fall within the company's traditionally strong therapeutic areas of infectious diseases and diabetes, while four novel candidates in late-stage Phase III trials are focused on chronic respiratory diseases and oncology.

"We have steered clear of overcrowded segments such as lung cancer and breast cancer. Instead, we are actively exploring tumor types with large patient populations but limited effective treatment options, including colorectal, pancreatic, liver and kidney cancers," he said.

Li Baiyong, chief science officer at Akeso, said the favorable external environment will continue to foster innovation in the sector.

He said that the high execution efficiency of R&D in China, combined with relatively low costs for personnel, equipment and manufacturing facilities, are key draws for multiple international pharmaceutical companies seeking partnerships with Chinese firms.